利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.034 秒)

    USE OF B LYMPHOCYTE STIMULATOR PROTEIN ANTAGONISTS TO TREAT ASTHMA AND OTHER ALLERGIC AND INFLAMMATORY CONDITIONS OF THE RESPIRATORY SYSTEM
    1.
    发明申请
    USE OF B LYMPHOCYTE STIMULATOR PROTEIN ANTAGONISTS TO TREAT ASTHMA AND OTHER ALLERGIC AND INFLAMMATORY CONDITIONS OF THE RESPIRATORY SYSTEM 审中-公开
    使用B淋巴细胞刺激素蛋白拮抗剂治疗呼吸系统的哮喘和其他过敏和炎症反应的条件

    公开(公告)号：US20110311548A1

    公开(公告)日：2011-12-22

    申请号：US13163593

    申请日：2011-06-17

    申请人： Heather Wasserman ,  Timothy L. Carlson ,  Thi-Sau Migone ,  Madhav Devalaraja

    发明人： Heather Wasserman ,  Timothy L. Carlson ,  Thi-Sau Migone ,  Madhav Devalaraja

    IPC分类号： A61K39/395 ,  A61P11/06 ,  A61P11/00 ,  A61K38/16 ,  A61K39/35

    CPC分类号： C07K16/2875 ,  A61K2039/505 ,  C07K16/244 ,  C07K2317/21 ,  C07K2317/622 ,  C07K2317/76

    摘要： The invention relates to methods of preventing, treating, and ameliorating asthma, allergen-induced respiratory symptoms, and/or an allergic or inflammatory condition of the lung or respiratory system in a patient by administering B Lymphocyte Stimulator antagonists. In addition, the invention provides a method of reducing total serum IgE levels in a patient suffering from asthma, and/or an allergic or inflammatory condition of the lung or respiratory system by administering B Lymphocyte Stimulator antagonists. The invention further provides a method of treating, preventing or ameliorating an allergen-induced airway hyper responsiveness or increase in mucus-containing cells and/or mucus accumulation or production in the airway epithelium of a patient by administering B Lymphocyte Stimulator antagonist.

    摘要翻译： 本发明涉及通过施用B淋巴细胞刺激物拮抗剂来预防，治疗和改善患者的肺或呼吸系统的哮喘，变应原诱导的呼吸症状和/或过敏性或炎症状态的方法。 此外，本发明提供了通过施用B淋巴细胞刺激物拮抗剂降低患有哮喘和/或肺或呼吸系统的过敏或炎性疾病的患者中的总血清IgE水平的方法。 本发明还提供了一种通过施用B淋巴细胞刺激剂拮抗剂来治疗，预防或改善变应原诱导的气道高反应性或增加含粘液的细胞和/或患者气道上皮中的粘液积聚或产生的方法。

    Antibodies That Specifically Bind to DR3
    2.
    发明申请
    Antibodies That Specifically Bind to DR3 审中-公开
    具体绑定到DR3的抗体

    公开(公告)号：US20120014950A1

    公开(公告)日：2012-01-19

    申请号：US13217023

    申请日：2011-08-24

    申请人： Thi-Sau Migone ,  Chih-Hung Lo ,  Luke Oh ,  Heather Wasserman ,  Madhav Devalaraja ,  Matthew J. Bernett

    发明人： Thi-Sau Migone ,  Chih-Hung Lo ,  Luke Oh ,  Heather Wasserman ,  Madhav Devalaraja ,  Matthew J. Bernett

    IPC分类号： A61K39/395 ,  A61P29/00 ,  A61P37/02 ,  A61P19/10 ,  A61P1/00 ,  A61P25/00 ,  A61P37/08 ,  A61P35/00 ,  C07K16/00 ,  A61P19/02

    CPC分类号： C07K16/2878 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/74 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

    摘要： The present invention relates to antibodies, antibody fragments, and related molecules that specifically bind to DR3 receptors. Such antibodies have uses, for example, in the prevention, detection, diagnosis, treatment or amelioration of a disease or disorder, especially inflammatory and autoimmune diseases and other immune system disorders, such as Crohn's disease, colitis, Inflammatory Bowel Disease, arthritis, asthma, Multiple Sclerosis, atherosclerosis, and allergic disorders. The invention also relates to nucleic acid molecules encoding anti-DR3 receptor antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder, especially inflammatory or autoimmune disorders, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that specifically bind to DR3 receptor.

    摘要翻译： 本发明涉及特异性结合DR3受体的抗体，抗体片段和相关分子。 这样的抗体具有例如用于预防，检测，诊断，治疗或改善疾病或病症，特别是炎症和自身免疫疾病和其他免疫系统疾病如克罗恩病，结肠炎，炎症性肠病，关节炎，哮喘 ，多发性硬化症，动脉粥样硬化和过敏性疾病。 本发明还涉及编码抗DR3受体抗体的核酸分子，含有这些核酸的载体和宿主细胞及其制备方法。 本发明涉及用于预防，检测，诊断，治疗或改善疾病或病症，特别是炎性或自身免疫性疾病的方法和组合物，其包括向动物（优选人）施用有效量的一种或多种抗体或片段或 其变体或相关分子，其特异性结合DR3受体。

    Antibodies to M-CSF
    4.
    发明申请
    Antibodies to M-CSF 有权
    M-CSF抗体

    公开(公告)号：US20050059113A1

    公开(公告)日：2005-03-17

    申请号：US10938353

    申请日：2004-09-09

    申请人： Vahe Bedian ,  Madhav Devalaraja ,  Ian Foltz ,  Mary Haak-Frendscho ,  Sirid-Aimee Kellermann ,  Joseph Low ,  James Mobley

    发明人： Vahe Bedian ,  Madhav Devalaraja ,  Ian Foltz ,  Mary Haak-Frendscho ,  Sirid-Aimee Kellermann ,  Joseph Low ,  James Mobley

    IPC分类号： A61P29/00 ,  A61P35/00 ,  C07K16/24 ,  G06F20060101 ,  G06Q30/00 ,  C07H21/04 ,  C12N5/06

    CPC分类号： C07K16/243 ,  A61K38/193 ,  A61K39/395 ,  A61K2039/505 ,  C07K16/24 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  G06Q30/02 ,  G06Q30/0601 ,  G06Q40/04 ,  G06Q50/12 ,  Y02A50/412

    摘要： The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also relates to human anti-M-CSF antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-M-CSF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-M-CSF antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-M-CSF antibodies. The invention also relates to transgenic animals and transgenic plants comprising nucleic acid molecules of the present invention.

    摘要翻译： 本发明涉及特异性结合M-CSF，优选人M-CSF的抗体及其抗原结合部分，其功能是抑制M-CSF。 本发明还涉及人抗M-CSF抗体及其抗原结合部分。 本发明还涉及嵌合，双特异性，衍生的单链抗体或融合蛋白的部分的抗体。 本发明还涉及衍生自人抗M-CSF抗体的分离的重链和轻链免疫球蛋白和编码这种免疫球蛋白的核酸分子。 本发明还涉及制备人抗M-CSF抗体的方法，包含这些抗体的组合物和使用该抗体和组合物进行诊断和治疗的方法。 本发明还提供使用编码包含人抗M-CSF抗体的重和/或轻免疫球蛋白分子的核酸分子的基因治疗方法。 本发明还涉及包含本发明的核酸分子的转基因动物和转基因植物。

    Inhibitors of colony stimulating factors
    6.
    发明申请
    Inhibitors of colony stimulating factors 审中-公开
    抑制因子的集落刺激因子

    公开(公告)号：US20070059280A1

    公开(公告)日：2007-03-15

    申请号：US11519502

    申请日：2006-09-12

    申请人： Madhav Devalaraja ,  Joseph Low

    发明人： Madhav Devalaraja ,  Joseph Low

    IPC分类号： A61K38/20 ,  A61K38/19 ,  A61K39/395

    CPC分类号： C07K16/243 ,  A61K2039/505

    摘要： A hematopoetic factor called “colony stimulating factor” (CSF) is capable of synergizing the attracting capabilities of chemokines and of inducing the accumulation and/or activation in vitro and in vivo of key components of inflammatory responses. Various types of agents that inhibit or otherwise hinder the production, release or activity of CSF could be used therapeutically in the treatment of ischemia and other inflammatory diseases, such as autoimmune disease, and various chronic inflammatory diseases such as rheumatoid arthritis and psoriasis.

    摘要翻译： 称为“集落刺激因子”（CSF）的造血因子能够协同趋化因子的吸引能力和诱导炎症反应的关键组分的体外和体内的积累和/或活化。 抑制或阻碍CSF的产生，释放或活性的各种类型的药剂可用于治疗缺血和其它炎性疾病如自身免疫性疾病和各种慢性炎性疾病如类风湿性关节炎和牛皮癣的治疗。